Tempest Therapeutics CFO Resigns; Nicholas Rossettos Appointed

What Happened
Tempest Therapeutics, Inc. filed an 8‑K (Aug 24, 2026) reporting that Justin Trojanowski notified the company on Aug 18, 2026 that he will resign as Principal Financial Officer and Principal Accounting Officer, effective Sept 1, 2026. On that same date, the Board appointed Nicholas Rossettos (age 60) as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary.

Key Details

• Resignation notice: Justin Trojanowski notified the company on Aug 18, 2026; resignation effective Sept 1, 2026.
• Appointment: Nicholas Rossettos named CFO and Principal Accounting Officer effective Sept 1, 2026.
• Experience: Mr. Rossettos has >30 years of financial experience, served as financial advisor to TransCode Therapeutics since Apr 2025, was Interim CFO of Sernova Corp. (Mar–Oct 2024), and has provided CFO consulting since 2012; previously CFO of Egenix (2006–2012).
• Credentials & agreements: Rossettos is a certified public accountant with an A.B. in Economics (Princeton) and an M.B.A. in Accounting (Northeastern); he will enter the company’s standard indemnification agreement.
• No related-party issues: No family relationships or arrangements led to his appointment; no transactions involving him require Item 404(a) disclosure.

Why It Matters
A change in the company’s principal financial officer is material because the CFO handles financial reporting, capital-raising and investor communications. Investors should note the effective date (Sept 1, 2026) and that Rossettos brings extensive biopharma finance and CFO experience; the filing reports no related-party concerns or disclosure issues arising from the appointment.